zurück zur Startseite
Zentrale Tel.: 06221-560
Molecular Medicine Partnership Unit

 

Chronic Kidney Disease

Matthias Gaida, Julio Saez-Rodriguez, Christoph Merten and Rainer Pepperkok

Our research interest

Chronic kidney disease (CKD) affects around 10% of the population in the Western world, has no specific treatment, and leads to kidney failure. Its pathomechanism is organ destruction through fibrosis, a process mainly driven by uncontrolled growth of myofibroblasts that produce large amounts of extracellular matrix. However, its molecular basis is poorly understood. We want to identify and understand the signalling events that lead to uncontrolled growth of myofibroblasts and ultimately the onset of CKD.

 

We will develop cutting edge microscopy and microfluidics technologies to study the response of patient biopsies to large numbers of biological perturbations. We will expand our existing readouts to phenotypes and RNA expression. We will analyse the data computationally and link the results to the patient’s pathological status and clinical outcome. For this, we will adapt our methodology (Eduati et al., 2018) to build mechanistic signalling models. These models will be built from the microfluidics perturbation data and existing signalling pathway knowledge (Türei, Korcsmaros, and Saez-Rodriguez 2016).



Background

A powerful tool to understand and treat pathophysiologies is the generation of large-scale datasets which report the responses of cells to biological perturbations. A new technology which we have developed (Eduati et al., 2018), allows us to perform such studies ex vivo on small biological samples obtained from patients (Eduati et al., 2018). We used a Caspase 3 reporter to the samples as a proxy for apoptosis. While limited, the reporter data can be used to build mechanistic and predictive models of these pathways (Eduati et al., 2018). By also including higher content readouts via microscopy and RNA-sequencing, we will drastically increase the number of processes that can be analysed.


Goal

Our goal is to understand the pathophysiology of CKD. The immediate outcome will be an understanding of which factors and signalling pathways drive kidney fibrosis, ultimately leading to CKD.

 

Furthermore, it will reveal common features and differences between the multiple CKD types, and eventually provide biomarkers and novel drug targets that can be further taken into clinical studies.

 

More generally, we aim to develop a high content platform for personalised therapy of kidney (and other) diseases.

 

Collaborators

Claudia Sommerer, Kidney Center Heidelberg

Martin Zeier, Kidney Center Heidelberg

 

Important Publications

A microfluidics platform for combinatorial drug screening on cancer biopsies.

Eduati F, Utharala R, Madhavan D, Neumann UP, Longerich T, Cramer T, Saez-Rodriguez J, Merten CA.

Nat Commun. 2018 Jun 22;9(1):2434. doi: 10.1038/s41467-018-04919-w. PMID:29934552

 

Patient-Specific Logic Models of Signaling Pathways from Screenings on Cancer Biopsies to Prioritize Personalized Combination Therapies.

Eduati, F., P. Jaaks, C. A. Merten, and M. J. Garnett. 2018.

bioRxiv. doi: 10.1101/422998

 

OmniPath: guidelines and gateway for literature-curated signaling pathway resources. 

Türei D, Korcsmáros T, Saez-Rodriguez J. 

Nat Methods. 2016 Nov 29;13(12):966-967. doi: 10.1038/nmeth.4077. No abstract available. PMID: 27898060


Print Diese Seite per E-Mail weiterempfehlen